Omega-3 fatty acid derivative DHEA reduced seizures in mice by activating CB1 receptors
The omega-3 endocannabinoid DHEA (from DHA) was more potent than its parent fatty acid in raising seizure thresholds in mice, acting through CB1 but not CB2 receptors, while the EPA-derived equivalent EPEA had no effect.
Quick Facts
What This Study Found
DHEA (100-300 uM) significantly increased seizure threshold within 10 minutes, more potently than its parent molecule DHA (which required 300 uM and 15 minutes). EPEA had no effect at any dose. The CB1 antagonist AM251 fully blocked the anti-seizure effects of both DHA and DHEA, while the CB2 antagonist AM630 did not.
Key Numbers
DHEA effective at 100 and 300 uM at 10 minutes; DHA effective at 300 uM at 15 minutes; EPEA ineffective at 300 and 1000 uM; AM251 (CB1 antagonist) fully blocked effects; AM630 (CB2 antagonist) did not block effects
How They Did This
Mice received intracerebroventricular injections of DHA, DHEA, EPEA, and cannabinoid receptor antagonists. Seizure threshold was measured by intravenous PTZ infusion at 10 and/or 15 minutes post-administration.
Why This Research Matters
This is the first report showing that DHEA, an omega-3 endocannabinoid, has direct anti-seizure activity via CB1 receptors. This connects the well-known neuroprotective effects of omega-3 fatty acids to the endocannabinoid system, suggesting a new mechanism.
The Bigger Picture
Connecting omega-3 fatty acid neuroprotection to the endocannabinoid system opens new avenues for understanding both nutritional approaches to seizure management and the broader role of dietary lipids in brain function.
What This Study Doesn't Tell Us
Intracerebroventricular delivery is not clinically practical. Acute seizure model may not reflect chronic epilepsy. Chemical threshold model (PTZ) is one of several seizure types. Small sample sizes typical of pharmacological studies.
Questions This Raises
- ?Would dietary DHA supplementation increase brain DHEA levels enough to raise seizure thresholds?
- ?Could DHEA or a stabilized analog be developed as an anti-epileptic drug?
Trust & Context
- Key Stat:
- DHEA more potent than parent molecule DHA in raising seizure thresholds
- Evidence Grade:
- Novel mechanistic finding in an acute seizure model, but limited by non-translatable delivery route and acute testing paradigm.
- Study Age:
- Published in 2021.
- Original Title:
- The ω-3 endocannabinoid docosahexaenoyl ethanolamide reduces seizure susceptibility in mice by activating cannabinoid type 1 receptors.
- Published In:
- Brain research bulletin, 170, 74-80 (2021)
- Authors:
- Ghanbari, Mohammad-Mahdi(2), Loron, Ali Gharibi, Sayyah, Mohammad(3)
- Database ID:
- RTHC-03150
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
How are omega-3 fatty acids related to the endocannabinoid system?
DHA (an omega-3 fatty acid) is converted in the body to DHEA (docosahexaenoyl ethanolamide), which is structurally similar to the endocannabinoid anandamide. This study shows DHEA activates CB1 cannabinoid receptors to raise seizure thresholds.
Could fish oil help with seizures?
This study suggests a mechanism by which omega-3 fatty acids could influence seizure susceptibility through the endocannabinoid system. However, whether dietary DHA intake translates to meaningful brain DHEA levels and seizure protection requires further investigation.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-03150APA
Ghanbari, Mohammad-Mahdi; Loron, Ali Gharibi; Sayyah, Mohammad. (2021). The ω-3 endocannabinoid docosahexaenoyl ethanolamide reduces seizure susceptibility in mice by activating cannabinoid type 1 receptors.. Brain research bulletin, 170, 74-80. https://doi.org/10.1016/j.brainresbull.2021.02.011
MLA
Ghanbari, Mohammad-Mahdi, et al. "The ω-3 endocannabinoid docosahexaenoyl ethanolamide reduces seizure susceptibility in mice by activating cannabinoid type 1 receptors.." Brain research bulletin, 2021. https://doi.org/10.1016/j.brainresbull.2021.02.011
RethinkTHC
RethinkTHC Research Database. "The ω-3 endocannabinoid docosahexaenoyl ethanolamide reduces..." RTHC-03150. Retrieved from https://rethinkthc.com/research/ghanbari-2021-the-3-endocannabinoid-docosahexaenoyl
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.